Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Antitumor activity of solamargine in mouse melanoma model: relevance to clinical safety

Full text
Furtado, Ricardo Andrade [1] ; Ozelin, Saulo Duarte [1] ; Ferreira, Natalia Helen [1] ; Miura, Barbara Ayumi [1] ; Almeida Junior, Silvio [1] ; Magalhaes, Georgia Mode [1] ; Nassar, Eduardo Jose [1] ; Miranda, Mariza Abreu [2] ; Bastos, Jairo Kenupp [2] ; Tavares, Denise Crispim [1]
Total Authors: 10
[1] Univ Franca, Ave Dr Armando Salles Oliveira, 201 Parque Univ, BR-14404600 Franca, SP - Brazil
[2] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Web of Science Citations: 0

Melanoma is the most aggressive type of skin cancer, and thus it is important to develop new drugs for its treatment. The present study aimed to examine the antitumor effects of solamargine a major alkaloid heteroside present in Solanum lycocarpum fruit. In addition solamargine was incorporated into nanoparticles (NP) of yttrium vanadate functionalized with 3-chloropropyltrimethoxysilane (YVO4:Eu3+:CPTES:SM) to determine antitumor activity. The anti-melanoma assessment was performed using a syngeneic mouse melanoma model B16F10 cell line. In addition, systemic toxicity, nephrotoxic, and genotoxic parameters were assessed. Solamargine, at doses of 5 or 10 mg/kg/day administered subcutaneously to male C57BL/6 mice for 5 days, decreased tumor size and frequency of mitoses in tumor tissue, indicative of a decrease in cell proliferation. Treatments with YVO4:Eu3+:CPTES:SM significantly reduced the number of mitoses in tumor tissue, associated with no change in tumor size. There were no apparent signs of systemic toxicity, nephrotoxicity, and genotoxicity initiated by treatments either with solamargine alone or plant alkaloid incorporated into NP. The animals treated with YVO4:Eu3+:CPTES:SM exhibited significant increase in spleen weight accompanied by no apparent histological changes in all tissues examined. In addition, animals treated with solamargine (10 mg/kg/day) and YVO4:Eu3+:CPTES:SM demonstrated significant reduction in hepatic DNA damage which was induced by tumor growth. Therefore, data suggest that solamargine may be considered a promising candidate in cancer therapy with no apparent toxic effects. (AU)

FAPESP's process: 13/02744-7 - Antitumoral and toxicological potential of solamargine functionalized with yttrium vanadate nanoparticles
Grantee:Ricardo Andrade Furtado
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 13/13903-9 - Evaluation of genotoxic and antioxidant activities of Styrax camporum hydroalcoholic extract and their chemical markers, egonol and homoegonol, and their influence on genomic and pre-neoplasic lesions
Grantee:Denise Crispim Tavares Barbosa
Support type: Regular Research Grants
FAPESP's process: 19/02641-0 - 6th Nano Today Conference
Grantee:Eduardo José Nassar
Support type: Research Grants - Meeting - Abroad